Second-line anticonvulsant treatment of neonatal seizures

Boylan, Geraldine B.; Rennie, J; Chorley, G.; Pressler, Ronit; Fox, Grenville; Farrer, Keith; Morton, Mark J.; Binnie, C. D.

doi:10.1212/01.wnl.0000106944.59990.e6

Cited by 149 publications

(131 citation statements)

References 4 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…Of the 21 articles included in the review, 20 were original studies, [15][16][17][18][19][20][21][22][23][24][25][26][28][29][30][31][32][33][34][35] with one companion abstract publication identified. 27 The companion abstract was included for completeness 27 and was not included for the rest of the review to avoid duplication of patient data.…”

Section: Resultsmentioning

confidence: 99%

“…There were 15 original retrospective studies 15,16,18,20,21,[23][24][25][26]28,30,[32][33][34][35] and five prospective studies. 17,19,22,29,31 Within the retrospective studies, 12 were retrospective case series 15,16,18,20,21,24,26,28,30,32,34,35 and the remaining three were retrospective case reports. 23,25,33 All studies were based in single centers.…”

Section: Resultsmentioning

confidence: 99%

“…Sixteen patients were studied as controls, using benzodiazepine-based therapies in the setting of RSE. 17,19 The age of patients studied ranged from 25 weeks' gestational age to 16 years. Study demographics and patient characteristics for the pediatric studies can be seen in Table 1, whereas treatment characteristics and seizure outcome are reported in Table 2.…”

Section: Resultsmentioning

confidence: 99%

“…17,19,22,29,31 Within these, three were prospective single-arm studies. The first study was a prospective study of 24 patients with unspecified underlying etiology, treated with a 1.6 to 2.2 mg/kg bolus, followed by a continuous infusion at 4.7 to 6.3 mg/kg/hour, for a duration of 0.1 to 9.3 days.…”

Section: The Prospective Studiesmentioning

confidence: 99%

“…17,19 The first study was a randomized control trial of 11 patients with hypoxia as the predominant etiology of their SE. These patients had all received phenobarbitone as the first-line AED, and if failure of seizure control was noted at 12 hours they were randomized to one of three groups.…”

Section: The Prospective Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Lidocaine for Status Epilepticus in Pediatrics

Zeiler

Teitelbaum

et al. 2015

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

Background: Our goal was to perform a systematic review of the literature on the use of intravenous lidocaine in pediatrics for status epilepticus (SE) and refractory status epilepticus (RSE) to determine its impact on seizure control. Methods: All articles from MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform (inception to November 2014), and gray literature were searched. The strength of evidence was adjudicated using both the Oxford and Grading of Recommendations Assessment, Development, and Evaluation methodologies by two independent reviewers. Results: Overall, 20 original studies were identified, with 19 manuscripts and one meeting abstract. Two hundred and thirty-five pediatric patients were treated for 252 episodes of SE/RSE. Patients had varying numbers of antiepileptic drugs (two to eight) on board before lidocaine therapy. During 20 of the 252 (7.9%) episodes of SE/RSE, phenytoin was on board. The dose regimen of lidocaine varied, with some using bolus dosing alone; others used a combination of bolus and infusion therapy. Overall, 60.0% of seizures responded to lidocaine, with complete cessation and greater than 50% reduction seen in 57.6% and 12.3%, respectively. Patient outcomes were sparingly reported. Conclusions: There currently exists Oxford level 2b, Grading of Recommendations Assessment Developement, and Evaluation C evidence to support the consideration of lidocaine for SE and RSE in the pediatric population. Further prospective studies of lidocaine administration in this setting are warranted.RÉSUMÉ: Traitement de l'état de mal épileptique par la lidocaïne en pédiatrie. Contexte : Nous avons effectué une revue systématique de la littérature à propos de l'utilisation de la lidocaïne par voie intraveineuse chez des enfants en état de mal épileptique (ÉMÉ) ou d'ÉMÉ résistant au traitement (ÉMÉR) afin de déterminer son impact sur le contrôle de l'ÉMÉ. Méthode : Nous avons recherché tous les articles sur ce sujet indexés dans MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform (du début jusqu' à novembre 2014) ainsi que la documentation parallèle. Deux réviseurs indépendants ont utilisé l'Oxford and Grading of Recommendations Assessment, Development and Evaluation pour évaluer la qualité des études. Résultats : En tout, 20 études originales ont été identifiées, dont 19 manuscrits et un résumé. Deux cent trente-cinq patients d'âge pédiatrique ont ainsi été traités au cours de 252 épisodes d'ÉMÉ/ÉMÉR. Les patients recevaient plusieurs médicaments antiépileptiques (de 2 à 8) avant le traitement par la lidocaïne. Au cours de 20 des 252 épisodes d'ÉMÉ/ÉMÉR (7,9%), le patient recevait de la phénytoïne. La dose de lidocaïne était variable : certains ont reçu seulement un bolus alors que d'autres ont reçu la lidocaïne en bolus et en perfusion. En tout, 60% des crises ont répondu à la lidocaïne avec arrêt complet de la crise chez 57,6% des...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: The Prospective Studiesmentioning

confidence: 99%

Section: The Prospective Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Lidocaine for Status Epilepticus in Pediatrics

Zeiler

Teitelbaum

et al. 2015

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

show abstract

Anticonvulsants for neonates with seizures

Booth

Evans

2004

Cochrane Database of Systematic Reviews

120

View full text Add to dashboard Cite

At present there is little evidence from randomised controlled trials to support the use of any of the anticonvulsants currently used in the neonatal period. In the literature, there remains a body of opinion that seizures should be treated because of the concern that seizures in themselves may be harmful, although this is only supported by relatively low grade evidence (Levene 2002; Massingale 1993). Development of safe and effective treatment strategies relies on future studies of high quality (randomised controlled trials with methodology that assures validity) and of sufficient size to have the power to detect clinically important reductions in mortality and severe neurodevelopmental disability in addition to any short term reduction in seizure burden.

show abstract

Antiseizure medications for neonates with seizures

Abiramalatha

Thanigainathan

Ramaswamy

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:1. To assess whether any anti-seizure medication (ASM) is more or less e ective than an alternative ASM (both ASMs used as first-, secondor third-line treatment) in achieving seizure control and improving neurodevelopmental outcomes in neonates with seizures. We will analyse EEG-confirmed seizures and clinically-diagnosed seizures separately. 2. To assess maintenance therapy with ASM compared to no maintenance therapy a er achieving seizure control. We will analyse EEGconfirmed seizures and clinically-diagnosed seizures separately. 3. To assess any ASM treatment compared to no ASM treatment for clinically-diagnosed or only-electrographic seizures.

show abstract

Second-line anticonvulsant treatment of neonatal seizures

Cited by 149 publications

References 4 publications

Lidocaine for Status Epilepticus in Pediatrics

Lidocaine for Status Epilepticus in Pediatrics

Anticonvulsants for neonates with seizures

Antiseizure medications for neonates with seizures

Contact Info

Product

Resources

About